Johnson & Johnson said worldwide sales for Q3 of fiscal 2025 were $24.0 billion, an increase of 6.8%, including operational growth of 5.4%, and sales for the 9 months ended were $69.6 billion, an increase of 5.0%, including operational growth of 4.7%.

10-QQuarterly reportFiled Oct 22, 2025Period of report Sep 28, 2025Summary published (UTC) Oct 10, 2026

Key points

AI summary

Johnson & Johnson said worldwide sales for Q3 of fiscal 2025 were $24.0 billion, an increase of 6.8%, including operational growth of 5.4%, and sales for the 9 months ended were $69.6 billion, an increase of 5.0%, including operational growth of 4.7%.
The company said the negative impact of the STELARA sales decline due to biosimilar competition on worldwide operational sales growth was approximately 6.4% for Q3 and approximately 6.1% for the 9 months.
Johnson & Johnson said earnings before provision for taxes on income for the 9 months of fiscal 2025 were $27.6 billion, representing 39.7% of sales, and included the reversal of approximately $7.0 billion of the talc reserve. For the 9 months of fiscal 2024, earnings before provision for taxes on income were $12.8 billion and included charges for talc matters of approximately $5.1 billion.
The company said that as of September 28, 2025, cash, cash equivalents and current marketable securities were approximately $18.6 billion, notes payable and long-term debt were approximately $45.8 billion, and net debt was $27.2 billion.

Key figures

Quarter ended September 28, 2025

Revenue: $24.0B
Net income: $5.2B
EPS: $2.12
Gross profit: $16.7B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q3 2025 and 9-Month Sales

Johnson & Johnson said worldwide sales for Q3 of fiscal 2025 were $24.0 billion, an increase of 6.8%, including operational growth of 5.4%, and sales for the 9 months ended were $69.6 billion, an increase of 5.0%, including operational growth of 4.7%.

Source · Based on the MD&A text of the filing

STELARA Sales Decline Impact

The company said the negative impact of the STELARA sales decline due to biosimilar competition on worldwide operational sales growth was approximately 6.4% for Q3 and approximately 6.1% for the 9 months.

Source · Based on the MD&A text of the filing

9-Month Earnings Before Provision for Taxes on Income and Talc Reserve Reversal

Johnson & Johnson said earnings before provision for taxes on income for the 9 months of fiscal 2025 were $27.6 billion, representing 39.7% of sales, and included the reversal of approximately $7.0 billion of the talc reserve. For the 9 months of fiscal 2024, earnings before provision for taxes on income were $12.8 billion and included charges for talc matters of approximately $5.1 billion.

Source · Based on the MD&A text of the filing

Cash and Debt Position

The company said that as of September 28, 2025, cash, cash equivalents and current marketable securities were approximately $18.6 billion, notes payable and long-term debt were approximately $45.8 billion, and net debt was $27.2 billion.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.